A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

NCT01925274 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no safety or efficacy issues that contributed to this decision.

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: PF-05212384
DRUG: irinotecan
DRUG: Cetuximab
DRUG: Irinotecan

Sponsor

Pfizer